about
Immunogenicity of Biotherapeutics: Causes and Association with Posttranslational ModificationsPosttranslational Modifications and the Immunogenicity of BiotherapeuticsA consensus method for the prediction of 'aggregation-prone' peptides in globular proteins.Stability engineering of anti-EGFR scFv antibodies by rational design of a lambda-to-kappa swap of the VL framework using a structure-guided approachImmunogenicity of Isogenic IgG in Aggregates and Immune Complexes.Immune-tolerant elastin-like polypeptides (iTEPs) and their application as CTL vaccine carriersAntitumor activity of antibody against cytotoxic T lymphocyte epitope peptide of lymphocyte-specific protein tyrosine kinase.Recombinant Proteins and Monoclonal Antibodies.Retracted: Molecular characterization of excipients' preferential interactions with therapeutic monoclonal antibodies.Practical considerations in clinical strategy to support the development of injectable drug-device combination products for biologics.
P2860
Q26738810-5C8EA30F-5614-4C28-8D91-F0BFEFB75AF9Q26748614-45D0B0FB-8793-4C8F-87C2-C2398A49C4FFQ34552231-A7165944-B676-43A0-9D36-9CE81F4A8228Q35764163-28EF724F-3EDE-455F-9F64-C6FA7807654CQ36257660-25DEECEF-2E55-4849-8049-B2BCB4AE3E91Q39678040-3B298CC4-1B33-4C0B-8AC4-6A1462A572A9Q47547494-B2E20000-0721-4807-92E9-783998FDC249Q47602370-9581E968-5B13-42D6-B1F4-7E891F856F67Q47834868-98FF3A3A-35B4-4B9B-822B-39F0565AF611Q49881176-B15E8D66-AC2F-45E8-A9E2-D874ADA95112
P2860
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Aggregation, immune complexes and immunogenicity.
@en
Aggregation, immune complexes and immunogenicity.
@nl
type
label
Aggregation, immune complexes and immunogenicity.
@en
Aggregation, immune complexes and immunogenicity.
@nl
prefLabel
Aggregation, immune complexes and immunogenicity.
@en
Aggregation, immune complexes and immunogenicity.
@nl
P2860
P356
P1476
Aggregation, immune complexes and immunogenicity.
@en
P2093
Roy Jefferis
P2860
P304
P356
10.4161/MABS.3.6.17611
P577
2011-11-01T00:00:00Z